Equities research analysts predict that Globus Medical Inc (NYSE:GMED) will report $0.34 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Globus Medical’s earnings. The lowest EPS estimate is $0.33 and the highest is $0.36. Globus Medical reported earnings of $0.31 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 9.7%. The firm is scheduled to announce its next earnings results on Monday, February 26th.

According to Zacks, analysts expect that Globus Medical will report full-year earnings of $1.27 per share for the current fiscal year, with EPS estimates ranging from $1.25 to $1.30. For the next financial year, analysts expect that the firm will report earnings of $1.39 per share, with EPS estimates ranging from $1.34 to $1.50. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Globus Medical.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Wednesday, November 8th. The medical device company reported $0.30 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.30. Globus Medical had a net margin of 17.54% and a return on equity of 13.67%. The firm had revenue of $151.74 million during the quarter, compared to analysts’ expectations of $150.73 million. During the same period last year, the business earned $0.29 earnings per share. Globus Medical’s revenue was up 11.9% compared to the same quarter last year.

A number of brokerages have weighed in on GMED. Wells Fargo & Co upgraded shares of Globus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target for the company in a research report on Monday, December 4th. ValuEngine cut shares of Globus Medical from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. BidaskClub upgraded shares of Globus Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Bank of America upgraded shares of Globus Medical from an “underperform” rating to a “neutral” rating in a research report on Friday, November 10th. Finally, Gabelli reiterated a “buy” rating on shares of Globus Medical in a research report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $40.57.

In other news, insider A Brett Murphy sold 51,449 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $35.00, for a total value of $1,800,715.00. Following the completion of the transaction, the insider now owns 49,768 shares of the company’s stock, valued at $1,741,880. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, President Anthony L. Williams sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $38.30, for a total transaction of $574,500.00. Following the completion of the transaction, the president now directly owns 15,000 shares of the company’s stock, valued at approximately $574,500. The disclosure for this sale can be found here. In the last three months, insiders sold 124,908 shares of company stock valued at $4,747,975. Insiders own 28.21% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of GMED. Janus Henderson Group PLC boosted its stake in shares of Globus Medical by 260.0% in the second quarter. Janus Henderson Group PLC now owns 2,683,312 shares of the medical device company’s stock valued at $88,952,000 after purchasing an additional 1,938,039 shares during the period. NWQ Investment Management Company LLC purchased a new position in shares of Globus Medical in the third quarter valued at approximately $25,856,000. American Century Companies Inc. purchased a new position in shares of Globus Medical in the third quarter valued at approximately $24,126,000. Nuance Investments LLC boosted its stake in shares of Globus Medical by 207.5% in the third quarter. Nuance Investments LLC now owns 776,919 shares of the medical device company’s stock valued at $23,090,000 after purchasing an additional 524,248 shares during the period. Finally, Koch Industries Inc. boosted its stake in shares of Globus Medical by 3,950.6% in the second quarter. Koch Industries Inc. now owns 479,431 shares of the medical device company’s stock valued at $465,000 after purchasing an additional 467,595 shares during the period. 70.24% of the stock is owned by institutional investors and hedge funds.

Shares of Globus Medical (NYSE:GMED) opened at $42.97 on Wednesday. Globus Medical has a 12-month low of $25.67 and a 12-month high of $46.51. The stock has a market cap of $4,140.00, a PE ratio of 39.06, a P/E/G ratio of 2.92 and a beta of 0.56.

TRADEMARK VIOLATION WARNING: “$0.34 EPS Expected for Globus Medical Inc (GMED) This Quarter” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/17/0-34-eps-expected-for-globus-medical-inc-gmed-this-quarter-2.html.

Globus Medical Company Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Get a free copy of the Zacks research report on Globus Medical (GMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.